In a significant move towards bolstering its oncology portfolio, GSK has entered into an exclusive license agreement with Hansoh Pharma for HS-20089, a B7-H4 targeted antibody-drug conjugate (ADC) currently in Phase I clinical trials in China for the treatment of ovarian and endometrial cancer. The agreement, which could be worth up to US$1.5 B, builds on GSK’s strategic R&D focus on tumour-cell targeting modalities as well as its significant medical and commercial expertise in gynecologic cancers.